259 related articles for article (PubMed ID: 26482613)
1. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.
Bu M; Shen Y; Seeger WL; An S; Qi R; Sanderson JA; Cai Y
Tumour Biol; 2016 Mar; 37(3):3949-56. PubMed ID: 26482613
[TBL] [Abstract][Full Text] [Related]
2. Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients.
Li X; Chen Y; Liu X; Zhang J; He X; Teng G; Yu D
Int Immunopharmacol; 2017 Mar; 44():153-159. PubMed ID: 28103502
[TBL] [Abstract][Full Text] [Related]
3. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
4. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer.
Liu JF; Wu L; Yang LL; Deng WW; Mao L; Wu H; Zhang WF; Sun ZJ
J Exp Clin Cancer Res; 2018 Mar; 37(1):44. PubMed ID: 29506555
[TBL] [Abstract][Full Text] [Related]
5. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells.
Fialová A; Partlová S; Sojka L; Hromádková H; Brtnický T; Fučíková J; Kocián P; Rob L; Bartůňková J; Spíšek R
Int J Cancer; 2013 Mar; 132(5):1070-9. PubMed ID: 22865582
[TBL] [Abstract][Full Text] [Related]
7. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
Wang W; Zou W; Liu JR
Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
[No Abstract] [Full Text] [Related]
9. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.
Knutson KL; Maurer MJ; Preston CC; Moysich KB; Goergen K; Hawthorne KM; Cunningham JM; Odunsi K; Hartmann LC; Kalli KR; Oberg AL; Goode EL
Cancer Immunol Immunother; 2015 Dec; 64(12):1495-504. PubMed ID: 26298430
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma.
Cai C; Zhang J; Li M; Wu ZJ; Song KH; Zhan TW; Wang LH; Sun YH
Tumour Biol; 2016 Jun; 37(6):8209-18. PubMed ID: 26715281
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
Watanabe Y; Katou F; Ohtani H; Nakayama T; Yoshie O; Hashimoto K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):744-52. PubMed ID: 20303300
[TBL] [Abstract][Full Text] [Related]
13. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
14. Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer.
Xu Y; Chen L; Xu B; Xiong Y; Yang M; Rui X; Shi L; Wu C; Jiang J; Lu B
Cell Physiol Biochem; 2017; 41(2):475-483. PubMed ID: 28214872
[TBL] [Abstract][Full Text] [Related]
15. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
Zhu Q; Wu X; Wu Y; Wang X
Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
[TBL] [Abstract][Full Text] [Related]
16. FoxP3+ regulatory T cells in peripheral blood of patients with epithelial ovarian cancer.
Erfani N; Hamedi-Shahraki M; Rezaeifard S; Haghshenas M; Rasouli M; Samsami Dehaghani A
Iran J Immunol; 2014 Jun; 11(2):105-12. PubMed ID: 24975967
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
Bachmayr-Heyda A; Aust S; Heinze G; Polterauer S; Grimm C; Braicu EI; Sehouli J; Lambrechts S; Vergote I; Mahner S; Pils D; Schuster E; Thalhammer T; Horvat R; Denkert C; Zeillinger R; Castillo-Tong DC
BMC Cancer; 2013 Sep; 13():422. PubMed ID: 24044611
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
Zhu S; Lin J; Qiao G; Xu Y; Zou H
Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
[TBL] [Abstract][Full Text] [Related]
19. Follicular regulatory T cells infiltrated the ovarian carcinoma and resulted in CD8 T cell dysfunction dependent on IL-10 pathway.
Li L; Ma Y; Xu Y
Int Immunopharmacol; 2019 Mar; 68():81-87. PubMed ID: 30616170
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
